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Abstract
Background.Collapsing glomerulopathy (CG) is a glomer-
ulonephritis seen in association with human immunodefi-
ciency virus (HIV) infection, known as HIV-associated
nephropathy (HIVAN), and less frequently observed in
non-HIV-infected patients.
Method. The aim of this study was to review the histo-
logical and clinical findings of all CG diagnosed since
1981 in our laboratory.
Result. Since 1981, 18 kidney biopsies with collapsing
features were diagnosed among 6130 biopsies performed:
72.2% (n = 13) males, mean age 33.8 ± 9.7 years, 61.1%
(n = 11) of black ethnic origin. HIV infection was present
in 10 patients. Mean serum creatinine (Scr) was 4.7 ±
2.5 mg/dL, and mean proteinuria was 6.1 ± 5 g/24 h. Both
HIVAN and non-HIVAN patients were similar in terms of
age, gender and dialysis requirement.
In the HIVAN population, African origin was predominant
and more frequent than in the non-HIVAN population, Scr
was higher and proteinuria was less severe. Interstitial in-
filtrate, interstitial fibrosis and tubular atrophy were se-
vere, and the presence of microcystic dilatation of renal
tubules was more common. Immunofluorescence was
positive in six patients. In the non-HIVAN population, this
histological lesion was related to an infectious illness in 6/8
patients and to the use of illegal oral drugs in one patient.
Interstitial infiltrate, interstitial fibrosis and tubular atrophy
presented as moderate to severe, and tubular atrophy corre-
lated with dialysis requirement. Mesangial proliferation
was present in 3/8 patients, with C3 and IgA deposits.
Conclusion. CG is a rare podocytopathy. In this study, the
association between infection and CG is evident, and we
may suggest that infections could, in a direct or indirect
manner, be a trigger of podocyte injury.
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Introduction
Collapsing glomerulopathy (CG) is, according to Columbia
classification, an aggressive morphologic variant of focal
segmental glomerulosclerosis (FSGS) [1,2], characterized
by severe proteinuria, rapidly progressive renal failure and
poor response to therapy [2,3]. The pathological features of
CG are segmental or global glomerular capillary loop col-
lapse with marked proliferation and hypertrophy of overly-
ing podocytes associated to noticeable tubulointerstitial
disease [1].
This is a newly debated disease, seen usually in asso-
ciation with human immunodeficiency virus (HIV) infec-
tion, known as HIV-associated nephropathy (HIVAN), and
relatively rare in non-HIV-infected patients [4,5]. Although
in this group of patients, most cases are idiopathic [1], there
have been cases associated with systemic or febrile illness
[3,6–9] or drugs exposure [3,10–12]. Whether CG is asso-
ciated with HIV or with any other aetiology, the pathogen-
esis probably involves visceral epithelial cell injury, which
causes marked dysregulation of the normal podocyte
phenotype and aberrant proliferation of tubular epithelium,
leading to microcystic dilatation of renal tubules accompan-
ied by cellular infiltrate [3].
The aim of this study was to review the histological
characteristics and clinical findings on all native renal bi-
opsies with collapsing features received by our pathology
laboratory since 1981.
Materials and methods
Study design
This was a retrospective review of all biopsies with collapsing features
received by the Renal Pathology Laboratory of the Curry Cabral Hospital,
from 1981 to March 2010. Our laboratory receives biopsies from our hos-
pital, from the hospitals in the south of Portugal and from the Atlantic
Portuguese islands.
The biopsies were re-examined by two independent investigators.
Slides examined by light microscopy contained at least six glomeruli
per section, and at least one glomerulus with segmental or global capillary
collapse with wrinkling of the basement membrane and crowding of the
epithelial cells was required for the diagnosis of CG. The degree of active
interstitial infiltrate, interstitial fibrosis and tubular atrophy was estimated
as a percentage of the cortical involved, and was considered mild if <30%,
moderate if between 30 and 60% and severe if >60%. The presence of dila-
tation or microcysts of renal tubules, acute tubular necrosis and the vessel
status were noted. Immunofluorescence microscopy of each biopsy was re-
viewed. Electron microscopy was examined when available.
Clinical and laboratory data from these patients at the time of biopsy
were obtained. We recorded age, gender, race, presence of viral infections,
namely HIV, hepatitis B virus (HBV), hepatitis C virus (HCV) and cyto-
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megalovirus infection (CMV), presence of an acute febrile illness, auto-
immune or malignancy disease, drug abuse, regular medication, dialysis
requirement, serum creatinine (Scr) values, 24-h proteinuria and presence
of haematuria, serological study for autoimmune disease (antinuclear anti-
bodies, C3 and C4 levels), serum and urinary electrophorectic studies.
Type of treatment and time of follow-up were registered.
Statistical analysis
Data are presented as mean ± SD values for normally distributed variables
or as frequencies for categorical variables. Independent variables were
compared using the Mann–Whitney and the chi-square tests. All tests were
performed using the SPSS system 18.0, and a P < 0.05 was considered
statistically significant.
Results
Since 1981, our laboratory received 6130 native renal biop-
sies. In 413, we found histological features of FSGS and in
only 18 of these, features of collapsing glomerulosclerosis.
Prior to 1994 there were 154 cases of FSGS, but no CG. Our
first case was in 1994, in a non-HIV patient. Since 1994 and
up to 1998, there have been no known cases of CG in our
hospital. From 1998 to 2010, sporadic cases of CG have
been found, while the number of FSGS remained about
the same. HIVAN cases were mainly found before 2001
(Figure 1).
The baseline clinical characteristics of patients are sum-
marized in Table 1. A total of 18 patients were identified,
with a mean age of 33.7 ± 9.8 years. There was a predom-
inance of young males (72.2%, n = 13), and 61.1% of the
population were of African origin (n = 11). HIV1 infection
was present in 10 patients. Mean Scr was 4.7 ± 2.5 mg/dL,
and mean proteinuria was 6.1 ± 5 g/24 h. Dialysis was
required in 44.4% (n = 8/15) of patients.
Renal biopsy was performed due to rapidly progressive
renal insufficiency in nine patients, nephrotic syndrome in
seven patients and non-nephrotic proteinuria in two pa-
tients, both HIV infected.
We analysed the data from HIV- and non-HIV-infected
patients separately (Table 2). In regard to clinical charac-
teristics, no differences were found in terms of gender and
dialysis requirement: in both groups, themajority of patients
were male and acute dialysis was required in ~ 50%. Black
race was predominant in HIV patients, as compared to
Caucasian race in non-HIV patients, Scr was higher
and proteinuria was lower. Histological findings revealed
a comparable degree of glomeruli injury, with a similar
number of collapsed glomeruli and comparable extent
of interstitial fibrosis, but tubular atrophy and microcystic
dilatation were more evident in HIV patients. Electron
microscopy (Figure 2) was similar in both groups, al-
though in HIV-infected patients tubulovesicular bodies
were observed in endothelial cell cytoplasm. Outcome
was available in nine patients (Table 3), five HIV-infected
and four non-HIV-infected patients.
In the HIV population (n = 10), black race was pre-
dominant (80%). In this group, two patients had HCV
co-infection and a previous medical history of intravenous
drug abuse, and one patient had Kaposi sarcoma (with
HHV-8) and miliary tuberculosis. All 10 had AIDS criteria,
whereas highly active antiretroviral therapy (HAART) was
only used in two patients. CD4 count was low (mean level:
35 ± 9 cells/mm3), and HIV RNA levels were high (mean
level: 530,902 ± 2508 copies). There was a trend for higher
Scr and lower level of proteinuria compared with non-HIV
patients, and histological findings revealed a mean col-
lapsed glomeruli of 3.5 ± 3.2 (Figure 3), higher degree
of tubular atrophy and microcystic formation. Overall,
interstitial infiltrate, interstitial fibrosis and tubular atrophy
were considered severe: in four samples all features pre-
sented as severe, in one sample interstitial infiltrate and
interstitial fibrosis were severe and tubular atrophy was
moderate, in four samples interstitial infiltratewasmoderate
and interstitial fibrosis and tubular atrophy were severe, and
in one sample all features were moderate. The presence of
microcystic dilatation of renal tubules (Figure 4) was iden-
tified in 70%, in comparison to 25% in non-HIV patients.
Immunofluorescence was positive in six patients: two had
staining for C3, one for C3 and C1q, two for C3 and IgM
and one for IgM. No staining for IgAwas found.
Outcome was available for five patients (50%): two were
on dialysis at the time of diagnosis, and remained on dia-
lysis in spite of initiating HAART and died afterwards, two
had a favourable response to HAART, with reduced levelFig. 1. Distribution of collapsing glomerulopathy in the last 18 years.
Table 1. Clinical characteristics of the population
Variable Patients (n = 18)
Age (year) 33.7 ± 9.8
Gender
Male 72.2% (13)
Female 27.8% (5)
Caucasian race (%) 38.9% (7)
Black race (%) 61.1% (11)
Human immunodeficiency virus infection 55.6% (10)
Hepatitis B virus infection (%) 16.7% (3)
Hepatitis C virus infection (%) 11.1% (2)
Renal replacement therapy (%) 44.4% (8/15)
Serum creatinine (mg/dL) 4.7 ± 2.5
Proteinuria (g/24 h) 6.1 ± 5
Haematuria (%) 50% (9)
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of proteinuria and Scr, and one started HAART but, after
8 months, died due to complications of miliary tuberculosis.
In the non-HIV group (n = 8), the patients were slightly
younger (36.7 ± 9.9 vs 30 ± 8.9) and Caucasian race was
predominant (62.5%). In 6/8 patients, there was a concomi-
tant infection: five had an acute febrile illness (two had ac-
tive pulmonary tuberculosis, one had acute HBV infection,
one had acute CMVand Ascaris lombricoides infection and
one had community pneumonia with non-identified agent);
one patient had chronic HBV infection. One patient con-
sumed illegal oral drugs, namely amphetamines and co-
caine. No associated disease was identified in one young
female. All patients had negative serology for HCV and
for autoimmune diseases, and all had a urinary and serum
electrophoresis that excluded monoclonal gammopathy.
No neoplasm was identified by clinical examination. No
regular medication was noted. These patients had higher pro-
teinuria levels than HIV patients (7.9 ± 3.9 vs 5 ± 5.5 g/24 h)
and lower Scr values (although, not statistically significant).
Histological data revealed a trend for a lesser degree of
interstitial infiltrate, interstitial fibrosis and tubular atrophy,
classified overall as moderate to severe. Microcysts were
only found in two patients, one with acute HBV infection
and the other with acute pulmonary tuberculosis. Tubular
atrophy correlated with dialysis requirement (P < 0.05).
Immunofluorescence was positive in four patients: one
staining for C3 and IgM and in three patients C3 and IgA
deposits were identified. The patients with IgA deposition
found in renal biopsy presented with chronic HBV infec-
tion, use of illegal oral drugs and acute pneumonia.
Follow-up was known in 50% of these patients. Patient
number 7 was on dialysis at the time of diagnosis, started
prednisolone 1 mg/kg during 8 weeks, and as no improve-
ment was noted, steroids were stopped and he continued on
dialysis. Patient number 6, a young female, with a preserved
renal function (Scr 1 mg/dL), started steroids (methylpred-
nisolone 1 g/day, during 3 days, subsequently prednisolone
20 mg/day for 2 months tapered and stopped) and oral
cyclophosphamide (1.5 mg/kg/day), which was maintained
for 18 months. A reduction of proteinuria (11.4 g > 3 g) was
attained and renal function (Scr 1.5 mg/dL) was relatively
maintained. However, this patient abandoned her appoint-
ments and therapy, appearing 14 months afterwards with a
marked deterioration of renal function and proteinuria (Scr
4.2 mg/dL and proteinuria 6 g/day). No therapy was then
tried and she started dialysis 4 months later. Patient number
8, another female, has been under treatment in the last 2 years.
She started prednisolone (1mg/kg/day during 2months, then
tapered up to 20 mg/day) plus cyclosporine (2 mg/kg/day, in
order to maintain cyclosporine level of 90–100 ng/mL)
during 15 months. There was a marked reduction of protein-
uria (10.8 g > 3 g), but Scr increased (4 mg/dL > 4.2 mg/dL).
Table 2. Clinical characteristics according to the presence/absence of HIV infection
Variable HIV-infected patients (n = 10) Non-HIV-infected patients (n = 8)
Age (year) 36.7 ± 9.9 30 ± 8.9
Gender (%)
Male 80% (8) 62.5% (5)
Female 20% (2) 37.5% (3)
Black race (%) 80% (8) 37.5% (3)
Hepatitis B virus infection (%) 0% 25% (3)
Hepatitis C virus infection (%) 20% (2) 0%
Renal replacement therapy (%) 55.6% (5/9) 50% (3/6)
Serum creatinine (mg/dL) 5 ± 2.3 4.2 ± 2.7
Proteinuria (g/L) 5 ± 5.5 7.9 ± 3.9
Haematuria (%) 50% (5) 50% (4)
Mean glomeruli number 7.8 ± 3.8 9.7 ± 4.1
Mean collapsed glomeruli (n) 3.5 ± 3.2 3.8 ± 2.9
Mesangial proliferation with C3 and IgA deposits (%) 0% 37.5% (3)
Interstitial infiltrate (%)
Moderate 50% (5) 62.5% (5)
Severe 50% (4) 37.5% (3)
Interstitial fibrosis (%)
Moderate 10% (1) 50% (4)
Severe 90% (9) 50% (4)
Tubular atrophy (%)
Moderate 10% (1) 50% (4)
Severe 90% (9) 50% (4)
Microcystic dilatation of tubules 70% (7) 25% (2)
Fig. 2. Wrinkling of basement membrane. Hypertrophy of podocyte with
pedicel effacement (EM ×30,000).
CG in Portugal: a review of the histological and clinical findings 2211
 at U
niversity of W
ashington on D
ecem
ber 20, 2012
http://ndt.oxfordjournals.org/
D
ow
nloaded from
 
After a new biopsy which showed an increase in interstitial
f ibrosis, she started mycophenolate mofetil, and after
6 months, Scr significantly improved (Scr 2.1 mg/dL). Pa-
tient number 9 will be started shortly on prednisolone and
mycophenolate mofetil.
Discussion
In 1975 the term ‘malignant focal segmental glomerulo-
sclerosis’ was used to describe a rapidly progressive neph-
rotic syndrome [3,14], and the first case report of CG was
published in 1979. In 1984 the term HIVAN was used to
describe CG associated to HIV infection [13], which is fre-
quently seen in Afro-American patients [15–18]. Since
1986, the term CG was introduced to define a similar lesion
in non-HIV-infected patients [7,14]. Although CG is con-
sidered to be a variant of FSGS, Barisoni et al. proposed that
it should be considered a distinct disorder [19]. In accor-
dance, both FSGS and CG should be considered podocyto-
pathies, as injury to podocytes is the main cause for the
disease. FSGS is defined by the presence of focal and seg-
mental injury to glomeruli, foot process effacement and
podocytopenia. In comparison, CG is characterized by hy-
perplastic and hypertrophic podocytes, with collapse and
sclerosis of the entire glomerular tuft, along with podocyte
proliferation.
It is noteworthy to point out that the origin of the highly
proliferating cells around the glomeruli is still a controversy.
Recent studies have shown that parietal epithelial cells
Table 3. Patients’ outcome
Patient Age Gender
HIV/
Non-HIV Other diseases Treatment
Scr
(mg/dL)a > b
Prot
(g/24 h)a> b RRTa> b Death Follow-up Comments
1 28 Male HIV Chronic HCV
infection
HAART 8.6 > 9 20 > na Yes > Yes Yes 10 months Never stopped
dialysis and died
2 25 Male HIV None HAART 7.5 > 8 22 > na Yes > Yes Yes 10 months Never stopped
dialysis and died
3 44 Male HIV None HAART 2 > 1.3 1.8 > 0.6 No > No No 9 months Lost follow-up
in 2008
4 36 Male HIV Mycobacterium
infection,
Kaposi
sarcoma
HAART 2.8 > 4.7 5 > 3 No > No Yes 8 months Died
5 28 Female HIV Chronic HBV
infection
HAART 2.8 > 1.9 3 > 1 No > No No 10 months Is under treatment
6 20 Female Non-HIV CMV infection
Ascaris
infection
PDN + CFF 1 > 8 11.4 > 3 No > Yes No 32months;
36 months
Started dialysis
after 32 months of
treatment. She is
still on dialysis.
7 26 Male Non-HIV Drug abuser PDN 8 > 8 7 > na Yes > Yes No 24 months Never stopped
dialysis
8 46 Female Non-HIV Pneumonia PDN +
CYA > MMF
4 > 2.1 10.8 > 1.9 No > No No 24 months Is under treatment
9 19 Female Non-HIV None None 2.3 > 2.3 4 > 4 No > No No 1 month Is going to
start treatment
na – not available.
aWhen biopsy was performed.
bAt the end of follow-up/renal survival.
Fig. 3. Collapsing capillaries with hyperplastic podocytes and protein
resorption droplets (Jones methenamine silver ×400).
Fig. 4. Microcystic dilatation of the tubules that are filledwith proteinaceous
casts (Masson trichrome stain ×400).
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(PEC) have the capacity to migrate and to differentiate into
podocytes, providing a continuous source of podocytes
[20]. Bariety et al. showed that parietal podocytes do exist
along normal human Bowman’s capsule and that these cells
express not only the epitopes of mature visceral podocytes
but also proproliferative epitopes, maintaining the ability to
divide [21]. This is highly complex, as PEC and podocytes
have an identical embryonic origin, and proliferating cells
may lack specific differentiation markers and probably ac-
quire a different phenotype. Assessment of the CD133+
CD24+ markers in adult human kidney identified a popula-
tion of renal progenitors, exhibiting self-renewal potential,
which are selectively localized at the urinary pole of Bow-
man’s capsule [22]. Accordingly, CD133+CD24+ progeni-
tors, or renopoietic system, might be responsible for tubular
epithelium and/or podocyte regeneration after injury. Fur-
thermore, a recent study from Smeets and co-workers [23],
based on human biopsies, showed that the renopoietic sys-
tem is responsible for exuberant repair of glomerular injury
resulting in CG. Interestingly, embryonic hyperplasia of the
Bowman’s capsule epithelium, which is the capacity of cells
from Bowman’s capsule acquires a primitive phenotype, has
been described many years ago [24]. In spite of these facts,
we believe that CG should be considered a new podocyto-
pathy, until further data are obtained.
In agreement with Barisoni et al., CG is associated with
a variety of disorders, which can be grouped in three areas:
idiopathic, genetic and secondary or reactive; the latter
ones are associated with virus, autoimmune disorders, ma-
lignancy, thrombotic microangiopathy, post-transplantation
and drugs [3,14,19].
Our study is the second which aims to review data onHIV
and non-HIV-related CG. The first study published in 1999
evaluated biopsies from 1979 to 1997, obtaining 60 CG, 42
non-HIV patients and 18 HIV patients [6]. Our first case of
CG was in 1994; since then, we received 18 kidney biopsies
with collapsing features, 10 HIV-related and 8 non-HIV-
related CG. These data suggest that CG is a very rare con-
dition in the Portuguese population (18/6130), even rarer
than in Macedonia residents, in which 16 biopsies were
found among 893 native renal biopsies [2]. It may be argued
that this number might be higher as only one collapsed
glomerulus is required for the diagnosis and this can be eas-
ily missed if the biopsy sample consists of only one small
core cortex. However, there are some clues, such as severe
tubulointerstitial disease and microcystic dilatation of tu-
bules that can imply the diagnosis. Of note, the number of
FSGS in our hospital remained similar during this time, pre-
senting a variable incidence range of 7 to 15.4% yearly.
In our study, patients were mainly black males at the third
decade of age. Laurinavicius et al. [6] found a female pre-
dominance, although age and race were similar to our data.
No differences in terms of gender, dialysis requirement and
degree of glomeruli injury between HIV and non-HIV pa-
tients were found, similar to Laurinavicius’data.
HIVAN was the most common cause for CG, accounting
for 55.6% of cases. However, Laurinavicius et al. have de-
monstrated that the majority of CG cases were in non-HIV-
infected patients, and in this group, only a minority (13/42)
was associated with autoimmune, lymphoproliferative and
viral disorders.
Our data showed that in non-HIV-related CG, Caucasian
race was predominant and the majority of cases (6/8) were
associated with a documented infection, namely acute HBV
infection, active pulmonary tuberculosis, acute CMVand A.
lombricoides infection and acute community pneumonia.
Indeed, several infectious diseases, other than HIV, are asso-
ciated with CG: CMV, HTLV-1, HCV, parvovirus B19,
Mycobacterium tuberculosis, Loa loa filariasis and visceral
leishmaniasis. Thus, it might be possible that HBV infection
may also be related to this injury. One case of non-HIV-
related CG was associated with illegal use of oral drugs,
namely amphetamines and cocaine. Interferon-alpha, val-
proic acid and pamidronate are some known causative
agents of CG. As far as we know, no similar cases relating
to amphetamines or cocaine with CG have been reported,
although recently collapsing lesions have been related with
anabolic steroids abuse [25].
Our HIV-infected patients had a higher percentage of mi-
crocystic dilatation of renal tubules, a higher level of tubular
atrophy and more severe renal dysfunction than non-HIV-
infected patients (Scr 5 ± 2.3 mg/dL vs 4.2 ± 2.7 mg/dL).
Besides glomerular lesions, HIVAN also develops prolif-
erative tubular lesions. Recently, a group of investigators
tried to address the importance of epithelial mesenchymal
transition (EMT) in HIVAN phenotype using Tg26 mice
[26], since EMT has been reported to contribute to the pro-
gression of renal fibrosis in other glomerular and tubuloin-
terstitial lesions [27]. Based on epithelial/mesenchymal
markers, this study showed the presence of a significant
number of myofibroblasts in periglomerular and peritubu-
lar lesions, leading to the conclusion that renal cells EMT
plays a role in the development of the proliferative pheno-
type in HIVAN. This issue needs further confirmation.
It is interesting to highlight that immunofluorescence of
non-HIV-related CG revealed the presence of IgA deposits
in 37.5% (3/8) of biopsies. The role of it is unclear: a pattern
of de novo CG, a pattern of IgA nephropathy or CG coex-
isting with IgA nephropathy. In fact, IgA nephropathy may
be associated with hepatic and/or pulmonary diseases,
which were identified in two patients with IgA deposition.
It is noteworthy to point that coexistence of CG and mem-
branous glomerulonephritis has been recently identified
[28].
The pathogenesis of CG remains unclear. In our popula-
tion, an association between CG and infections is demon-
strated. It has been proved that HIV1 gene products can
directly cause collapse of the capillaries [18,29–31]. This
raises the hypothesis that infected cellular elements and/or
host derived co-factors may be involved in the pathogenesis
of infection-associated CG. In addition, immunoglobulin
may induce CG [14]. Interestingly, rats subjected to im-
munoglobulin, obtained from patients with CG, may also
develop the disease [32]. This could be the underlying
mechanism for development of CG in autoimmune and ma-
lignancy disorders, viral infection and post-transplantation.
The role of genetic traits, such as the association between
CG andMHC genes, CG and genes encoding mitochondrial
function or genes linked to action myoclonus-renal syn-
drome and mandibuloacral dysplasia have also been found
[14]. Albaqumi et al. [3] propose a speculative ‘best-fit
model’ for CG based in models of response to death in epi-
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thelial cells. In this ‘best-fit model’, necrotic or apoptotic
epithelium due to an intrinsic or extrinsic insult, communi-
cates with adjacent cells, promoting their hyperplasia. This
aberrant proliferation culminates in capillary collapse and
microcystic formation. It also may be possible that a number
of different insults may be necessary to induce podocyte de-
regulation on a genetic sensible cell.
There is no established treatment for non-HIV-related
CG in comparison to treatment of HIVAN where HAART
seems to be effective. The therapeutic approach to non-
HIV-related CG is not easy, as the nature of the disease
is not yet totally understood and is not treated in separate
clinical trials. We feel that steroids alone are insufficient
for the treatment of this aggressive disease, and a combin-
ation of immunosuppressive drugs, consistent with Appel’s
recommendations [33], may be the best approach, except
for patients already on dialysis, in which benefits of the
therapy are reduced. Length of treatment is, similarly,
not certain. Data from Laurinavicius’ study showed that
of the 42 non-HIV patients treated with a combination of
steroids, cyclosporin A or other cytostatic therapy, the ma-
jority progressed to end-stage renal failure and 17% died
within 14 months of follow-up [6]. Mycophenolate mofetil
is an interesting drug due to its relative renal specificity
and lower incidence of side effects. It might be that in fu-
ture monoclonal antibodies, in particular rituximab, may
be used for CG. At least two reports has described success-
ful data [34,35]. Also, it is probable that CG associated to
secondary causes, in particular infections or cancer, may
remit with treatment of the underlying disease [36], which
is well known for other glomerular diseases such as mem-
branous glomerulonephritis associated with cancer.
HAART has been demonstrated to be effective for treat-
ment of HIVAN [37–42], suggesting that HIV patients
will have a better outcome, as no definitive treatment exists
for non-HIV patients. Nevertheless, CYC202, a cyclin-
dependent kinase inhibitor has promised good results for
treatment of CG in mice [5].
Unfortunately, the major limitation of this study is the
missing data on follow-up in half of the patients. Half of
the biopsies came from outside of our hospital. In addition,
some patients have abandoned nephrology and infectiology
appointments, which obviously cause missing prospective
data. Nevertheless, it seems that, in HIVAN, early treatment
with HAART appears to be effective for preserving renal
function and reducing proteinuria. For non-HIV patients,
immunosuppressive therapy with cyclosporine and/or my-
cophenolate mofetil seemed to allow the preservation of
renal function and the reduction of proteinuria when started
before initiating dialysis.
Conclusion
CG is a very rare condition in the Portuguese popula-
tion, it is mainly associated with infections, namely HIV,
HBV, CMVand pulmonary tuberculosis, affecting predom-
inantly male and black patients at the third decade of life.
No cases associated with malignancy or autoimmune dis-
eases were found. CG in HIV patients displayed a higher
percentage of microcystic dilatation of renal tubules. More
studies are needed to clarify the aetiology, the pathogenesis
and the treatment of CG.
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Abstract
Background. The clinical significance of focal segmental
glomerulosclerosis (FSGS) tip variant remains unclear.
With the aim to determine its clinical and histological fea-
tures, and natural history, we studied our cases of patients
with this glomerular lesion.
Methods. This is a retrospective analysis. All native renal
biopsies from patients diagnosed as FSGS, between 1998
and 2006, were revised for cases with tip variant. Glomer-
ulosclerosis (GS), segmental lesions and interstitial fibro-
sis (IF) were quantified. We analysed clinical and follow-
up data and compared with cases of FSGS not otherwise
specified (NOS).
Results. In 248 primary FSGS cases, 37 corresponded to
tip variant (14.9%). Median age was 17 years (range 1–
65); 13 (35.1%) patients were <15 years old, and 56.8%
were males. All patients had nephrotic proteinuria. At
diagnosis, there were no significant differences for age,
Glomerular tip variant of FSGS 2215
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